T. Piscopo, M. Azzopardi, and C. , Leishmaniasis, Postgraduate Medical Journal, vol.83, issue.976, pp.649-657, 2007.
DOI : 10.1136/pgmj.2006.047340corr1

R. Ashford, P. Desjeux, and P. Deraadt, Estimation of population at risk of infection and number of cases of Leishmaniasis, Parasitology Today, vol.8, issue.3, pp.104-105, 1992.
DOI : 10.1016/0169-4758(92)90249-2

C. King and A. Bertino, Asymmetries of Poverty: Why Global Burden of Disease Valuations Underestimate the Burden of Neglected Tropical Diseases, PLoS Neglected Tropical Diseases, vol.2, issue.3, p.209, 2008.
DOI : 10.1371/journal.pntd.0000209.g003

J. Kolaczinski, R. Reithinger, D. Worku, A. Ocheng, and J. Kasimiro, Risk factors of visceral leishmaniasis in East Africa: a case-control study in Pokot territory of Kenya and Uganda, International Journal of Epidemiology, vol.37, issue.2, pp.344-352, 2008.
DOI : 10.1093/ije/dym275

P. Desjeux, Leishmaniasis, Clinics in Dermatology, vol.14, issue.5, p.692, 2004.
DOI : 10.1016/0738-081X(96)00057-0
URL : https://hal.archives-ouvertes.fr/hal-01258695

R. Reithinger, J. Dujardin, H. Louzir, C. Pirmez, and B. Alexander, Cutaneous leishmaniasis, The Lancet Infectious Diseases, vol.7, issue.9, pp.581-596, 2007.
DOI : 10.1016/S1473-3099(07)70209-8

F. Chappuis, S. Sundar, A. Hailu, H. Ghalib, and S. Rijal, Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?, Nature Reviews Microbiology, vol.14, issue.11, pp.873-882, 2007.
DOI : 10.1038/nrmicro1748

S. Croft, S. Sundar, and A. Fairlamb, Drug Resistance in Leishmaniasis, Clinical Microbiology Reviews, vol.19, issue.1, pp.111-126, 2006.
DOI : 10.1128/CMR.19.1.111-126.2006

S. Nwaka and A. Hudson, Innovative lead discovery strategies for tropical diseases, Nature Reviews Drug Discovery, vol.4, issue.11, pp.941-955, 2006.
DOI : 10.1038/nrd2144

A. Davis, H. Murray, and E. Handman, Drugs against leishmaniasis: a synergy of technology and partnerships, Trends in Parasitology, vol.20, issue.2, pp.73-76, 2004.
DOI : 10.1016/j.pt.2003.11.006

D. Sereno, C. Da-silva, A. Mathieu-daude, F. Ouaissi, and A. , Advances and perspectives in Leishmania cell based drug-screening procedures, Parasitology International, vol.56, issue.1, pp.3-7, 2007.
DOI : 10.1016/j.parint.2006.09.001
URL : https://hal.archives-ouvertes.fr/hal-00376733

J. Mikus and D. Steverding, A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue??, Parasitology International, vol.48, issue.3, pp.265-269, 2000.
DOI : 10.1016/S1383-5769(99)00020-3

A. Ivens, C. Peacock, E. Worthey, L. Murphy, and G. Aggarwal, The Genome of the Kinetoplastid Parasite, Leishmania major, Science, vol.309, issue.5733, pp.436-442, 2005.
DOI : 10.1126/science.1112680

J. Zhang, T. Chung, and K. Oldenburg, A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays, Journal of Biomolecular Screening, vol.4, issue.2, pp.67-73, 1999.
DOI : 10.1177/108705719900400206

J. Zhang, T. Chung, and K. Oldenburg, Confirmation of Primary Active Substances from High Throughput Screening of Chemical and Biological Populations:?? A Statistical Approach and Practical Considerations, Journal of Combinatorial Chemistry, vol.2, issue.3, pp.258-265, 2000.
DOI : 10.1021/cc9900706

C. Crespi, V. Miller, and B. Penman, Microtiter Plate Assays for Inhibition of Human, Drug-Metabolizing Cytochromes P450, Analytical Biochemistry, vol.248, issue.1, pp.188-190, 1997.
DOI : 10.1006/abio.1997.2145

M. Vermeersch, R. Da-luz, K. Toté, J. Timmermans, and P. Cos, In Vitro Susceptibilities of Leishmania donovani Promastigote and Amastigote Stages to Antileishmanial Reference Drugs: Practical Relevance of Stage-Specific Differences, Antimicrobial Agents and Chemotherapy, vol.53, issue.9, pp.3855-3859, 2009.
DOI : 10.1128/AAC.00548-09

A. Jhingran, B. Chawla, S. Saxena, M. Barrett, and R. Madhubala, Paromomycin: Uptake and resistance in Leishmania donovani, Molecular and Biochemical Parasitology, vol.164, issue.2, pp.111-117, 2009.
DOI : 10.1016/j.molbiopara.2008.12.007

M. Junghae and J. Raynes, Activation of p38 Mitogen-Activated Protein Kinase Attenuates Leishmania donovani Infection in Macrophages, Infection and Immunity, vol.70, issue.9, pp.5026-5035, 2002.
DOI : 10.1128/IAI.70.9.5026-5035.2002

S. Bakunova, S. Bakunov, D. Patrick, E. Kumar, and K. Ohemeng, Structure???Activity Study of Pentamidine Analogues as Antiprotozoal Agents, Journal of Medicinal Chemistry, vol.52, issue.7, pp.2016-2035, 2009.
DOI : 10.1021/jm801547t

A. Ghosh, M. Rakshit, and D. Ghosh, Effect of berberine chloride on Leishmania donovani, Indian J Med Res, vol.78, pp.407-416, 1983.

T. Tiuman, T. Ueda-nakamura, G. Cortez, D. , D. Filho et al., Antileishmanial Activity of Parthenolide, a Sesquiterpene Lactone Isolated from Tanacetum parthenium, Antimicrobial Agents and Chemotherapy, vol.49, issue.1, pp.176-182, 2005.
DOI : 10.1128/AAC.49.11.176-182.2005

A. Haberkorn, The effect of nifurtimox on experimental infections with trypanosomatidae other than Trypanosoma cruzi, Zentralbl Bakteriol Orig A, vol.244, pp.331-338, 1979.

A. Gebre-hiwot, G. Tadesse, S. Croft, and D. Frommel, An in vitro model for screening antileishmanial drugs: the human leukaemia monocyte cell line, THP-1, Acta Tropica, vol.51, issue.3-4, pp.237-245, 1992.
DOI : 10.1016/0001-706X(92)90042-V

S. Croft, Y. V. Kendrick, and H. , Drug sensitivity of Leishmania species: some unresolved problems, Transactions of the Royal Society of Tropical Medicine and Hygiene, vol.96, issue.1, pp.127-129, 2002.
DOI : 10.1016/S0035-9203(02)90063-5

K. Stark and F. Guengerich, Characterization of Orphan Human Cytochromes P450, Drug Metabolism Reviews, vol.37, issue.2-3, pp.627-637, 2007.
DOI : 10.1016/j.bbrc.2006.04.080

S. Singh, Preclinical Pharmacokinetics: An Approach Towards Safer and Efficacious Drugs, Current Drug Metabolism, vol.7, issue.2, pp.165-182, 2006.
DOI : 10.2174/138920006775541552

S. St-george, J. Bishop, R. Titus, and C. Selitrennikoff, Novel Compounds Active against Leishmania major, Antimicrobial Agents and Chemotherapy, vol.50, issue.2, pp.474-479, 2006.
DOI : 10.1128/AAC.50.2.474-479.2006

E. Sharlow, D. Close, T. Shun, S. Leimgruber, and R. Reed, Identification of Potent Chemotypes Targeting Leishmania major Using a High-Throughput, Low-Stringency, Computationally Enhanced, Small Molecule Screen, PLoS Neglected Tropical Diseases, vol.8, issue.11, p.540, 2009.
DOI : 10.1371/journal.pntd.0000540.s003

N. Vieira, C. Herrenknecht, J. Vacus, A. Fournet, and C. Bories, Selection of the most promising 2-substituted quinoline as antileishmanial candidate for clinical trials, Biomedicine & Pharmacotherapy, vol.62, issue.10, pp.684-689, 2008.
DOI : 10.1016/j.biopha.2008.09.002

K. Kinnamon, E. Steck, P. Loizeaux, W. Hanson, W. Chapman et al., The antileishmanial activity of lepidines, Am J Trop Med Hyg, vol.27, pp.751-757, 1978.

T. Jha, S. Sundar, C. Thakur, J. Felton, and A. Sabin, A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India, Am J Trop Med Hyg, vol.73, pp.1005-1011, 2005.